Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 2002

Conditions
Essential Thrombocythaemia
Interventions
DRUG

Anagrelide

DRUG

Hydroxyurea

Trial Locations (24)

1090

Center AKH, Vienna

1097

Center Budapest, Budapest

1140

Center Hanusch, Vienna

2600

Center Vilnius, Vilnius

6020

Center Innsbruck, Innsbruck

12200

Center Berlin, Berlin

12808

Center Praha, Prague

27100

Center Pavia, Pavia

41100

Center Modena, Modena

62500

Center Brno, Brno

66113

Center Saarbrücken, Saarbrücken

77520

Center Olomouc, Olomouc

80331

Center Munich, Munich

89081

Center Ulm, Ulm

92118

Center Paris, Paris

169608

Center Singapore, Singapore

06111

Center Halle, Halle

80-211

Center Gdansk, Gdansk

40-027

Center Katowice, Katowice

31-501

Center Krakow, Krakow

93-510

Center Lodz, Lodz

20-079

Center Lublin, Lublin

02-097

Center Warszawa, Warsaw

Unknown

Center Ljubljana, Ljubljana

Sponsors
All Listed Sponsors
lead

AOP Orphan Pharmaceuticals AG

INDUSTRY

NCT01065038 - Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia | Biotech Hunter | Biotech Hunter